These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11829209)

  • 1. Frontotemporal dementia: clinical, neuroimaging, and molecular biological findings in 6 patients.
    Jauss M; Herholz K; Kracht L; Pantel J; Hartmann T; Jensen M; Essig M; Schröder J
    Eur Arch Psychiatry Clin Neurosci; 2001 Oct; 251(5):225-31. PubMed ID: 11829209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
    Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
    Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
    Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
    Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional correlates of t-Tau, p-Tau and Aβ₁₋₄₂ amyloid cerebrospinal fluid levels in Alzheimer's disease: a ¹⁸F-FDG PET/CT study.
    Chiaravalloti A; Martorana A; Koch G; Toniolo S; di Biagio D; di Pietro B; Schillaci O
    Nucl Med Commun; 2015 May; 36(5):461-8. PubMed ID: 25646706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging.
    Pijnenburg YA; Schoonenboom SN; Barkhof F; Knol DL; Mulder C; Van Kamp GJ; Van Swieten JC; Scheltens P
    J Neurol Neurosurg Psychiatry; 2006 Feb; 77(2):246-8. PubMed ID: 16421130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A biomarker study in long-lasting amnestic mild cognitive impairment.
    Cerami C; Dodich A; Iannaccone S; Magnani G; Santangelo R; Presotto L; Marcone A; Gianolli L; Cappa SF; Perani D
    Alzheimers Res Ther; 2018 Apr; 10(1):42. PubMed ID: 29695292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applied multimodal diagnostics in a case of presenile dementia.
    Schönecker S; Brendel M; Huber M; Vollmar C; Huppertz HJ; Teipel S; Okamura N; Levin J; Rominger A; Danek A
    BMC Neurol; 2016 Aug; 16():131. PubMed ID: 27506761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuroimaging of frontotemporal dementia].
    Blesa R
    Neurologia; 2000 Jan; 15 Suppl 1():30-2. PubMed ID: 10723172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease.
    Brettschneider J; Petzold A; Schottle D; Claus A; Riepe M; Tumani H
    Dement Geriatr Cogn Disord; 2006; 21(5-6):291-5. PubMed ID: 16484807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neuropathology and biochemistry of frontotemporal dementia.
    Munoz DG; Dickson DW; Bergeron C; Mackenzie IR; Delacourte A; Zhukareva V
    Ann Neurol; 2003; 54 Suppl 5():S24-8. PubMed ID: 12833365
    [No Abstract]   [Full Text] [Related]  

  • 11. Amyloid Abeta40 CSF concentrations correlate to frontal lobe atrophy in frontotemporal dementia.
    Andersen C; Jensen M; Lannfelt L; Lindau M; Wahlund LO
    Neuroreport; 2000 Feb; 11(2):287-90. PubMed ID: 10674472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.
    Smith R; Puschmann A; Schöll M; Ohlsson T; van Swieten J; Honer M; Englund E; Hansson O
    Brain; 2016 Sep; 139(Pt 9):2372-9. PubMed ID: 27357347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.
    Näslund J; Haroutunian V; Mohs R; Davis KL; Davies P; Greengard P; Buxbaum JD
    JAMA; 2000 Mar 22-29; 283(12):1571-7. PubMed ID: 10735393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report.
    Schroeter ML; Tiepolt S; Marschhauser A; Thöne-Otto A; Hoffmann KT; Barthel H; Obrig H; Sabri O
    BMC Neurol; 2015 Aug; 15():152. PubMed ID: 26303364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.
    Yakushev I; Muller MJ; Buchholz HG; Lang U; Rossmann H; Hampel H; Schreckenberger M; Fellgiebel A
    Curr Alzheimer Res; 2012 Feb; 9(2):241-7. PubMed ID: 22044023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau, ubiquitin, and alpha B-crystallin immunohistochemistry define the principal causes of degenerative frontotemporal dementia.
    Cooper PN; Jackson M; Lennox G; Lowe J; Mann DM
    Arch Neurol; 1995 Oct; 52(10):1011-5. PubMed ID: 7575218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.
    Green AJ; Harvey RJ; Thompson EJ; Rossor MN
    Neurosci Lett; 1999 Jan; 259(2):133-5. PubMed ID: 10025576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.